主动脉髂动脉闭塞性病变腔内重建十年经验:HERAB技术
本研究报告三级中心2012至2023年连续92例复杂主髂动脉闭塞性疾病患者采用HERAB技术行主动脉分叉腔内重建的10年结果。技术成功率93.5%,30天死亡率1.1%,5年一期、一期辅助和二期通畅率分别为68.8%、80.7%和89.5%。作者认为HERAB是CERAB安全有效的长期替代方案,具有保留侧支网络、可使用低剖面器械和费用较低的优势。
要点
- 92例复杂主髂动脉闭塞性疾病患者中97%为TASC II D级,68.5%因间歇性跛行手术。
- 技术成功率93.5%,30天死亡率1.1%,保肢率98%。
- 5年一期、一期辅助、二期通畅率分别为68.8%、80.7%、89.5%,免于靶病变血运重建率83.7%。
核心结论
- HERAB是CERAB安全有效的长期替代方案,具有保留侧支网络、可使用低剖面器械和费用较低的优势。
研究设计与样本
- 本研究为单中心回顾性研究,纳入2012至2023年三级中心连续92例因主髂动脉闭塞性疾病行HERAB技术主动脉分叉腔内重建的病例。
- 记录基线数据、手术数据、30天并发症和总生存率,分析通畅率和免于靶病变血运重建率,采用单变量分析识别通畅性丧失的预测因素。
主要发现
- 97%的病例AIOD分类为TASC II D级,63例(68.5%)血运重建指征为间歇性跛行。
- 技术成功率为93.5%,30天死亡率为1.1%。
- 5年一期、一期辅助和二期通畅率分别为68.8%、80.7%和89.5%,免于靶病变血运重建率为83.7%。
- 术前侧支网络在97%的病例中得以保留。
- 仅髂动脉对吻支架中使用LifeStream支架与通畅性丧失相关。
关键数值与推荐
- TASC II D级占97%,间歇性跛行占68.5%(63例)。
- 技术成功率93.5%,30天死亡率1.1%。
- 5年一期通畅率68.8%,一期辅助通畅率80.7%,二期通畅率89.5%,免于靶病变血运重建率83.7%。
- 术前侧支网络保留率97%,保肢率98%。
- 通畅性丧失时临床表现与初发事件相同者占52%。
临床怎么用
- 作者认为HERAB是CERAB安全有效的长期替代方案,具有保留侧支网络、可使用低剖面器械和费用较低的优势。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hybrid endovascular reconstruction of the aortic bifurcation (HERAB) is an alternative technique to covered endovascular reconstruction of aortic bifurcation (CERAB) developed in our tertiary center for complex (TransAtlantic Inter-Society Consensus C-D) aortoiliac occlusive disease (AIOD). The purpose of this study was to report our results at 10 years and try to identify factors influencing patency. METHODS: From 2012 to 2023, all consecutive cases requiring endovascular aortic bifurcation reconstruction with HERAB technique for AIOD were collected at our tertiary center. Baseline data, procedural data, their 30-days complications, and overall survival were recorded. Patency and freedom from target lesion revascularisation were analyzed. Univariate analysis was performed to identify predictors of patency loss. RESULTS: A total of 92 patients were included in the study. The AIOD was classified as TASC II D in 97% of cases, and indication for revascularisation was intermittent claudication in 63 cases (68.5%). Technical success rate was 93.5% and the 30-day mortality rate was 1.1%. Respective 5-year primary, primary assisted, and secondary patency rates were 68.8%, 80.7%, and 89.5%, with freedom from target lesion revascularisation rate of 83.7%. The collateral network patent before the surgery was preserved in 97% of cases. Only the use of a LifeStream stent for iliac kissing stent was associated with the loss of patency. In the case of patency loss, clinical presentation was the same as the onset event in 52% of cases. Overall, the limb salvage rate was 98%. CONCLUSION: HERAB represents a safe and effective long-term alternative to CERAB. This procedure offers an advantage of preserving the collateral network, allowing the use of low-profile devices, and less expensive procedure.
引用
- Roisin S, Cohen R, Ifergan G, et al. 10 Years' Experience of Endovascular Reconstruction of Aortoiliac Occlusive Lesions: HERAB Technique. Ann Vasc Surg. 2025. PMID: 40320206. doi:10.1016/j.avsg.2025.04.128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。